Parisa Zamiri
Company: Graybug Vision
Job title: Chief Medical Officer
Seminars:
Showcasing Anti-VEGF Biopolymer Conjugate With Improved Efficacy & Durability 5:00 pm
day: Day One
Panel Discussion: Future Directions for Anti-VEGF Therapies 12:10 pm
Increasing patient response rates, not just prolonging treatment duration New therapy formats (bispecifics) – how does dual-specificity open up a wide range of therapeutic applications for these multifactorial diseases? Combinatorial approaches – approaches that could potentially be used on patients currently refractory or not optimally treated with anti-VEGF-A therapy aloneRead more
day: Day One